Century Therapeutics Announces Two Upcoming Presentations at the ASGCT 28th Annual Meeting

Rhea-AI Summary

Century Therapeutics (NASDAQ: IPSC), a leading biotech company focused on developing innovative cell therapies, has announced two significant presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting in New Orleans.

The presentations will showcase their groundbreaking work in:

• A poster session featuring research on iPSC-derived therapies with TGF-b neutralizing capabilities for enhanced solid tumor treatment
• An oral presentation demonstrating advances in iPSC-derived CD4+ and CD8+ CD19 CAR T cells showing promising tumor control capabilities

Key details of the event:

• Location: New Orleans Ernest N. Morial Convention Center
• Dates: May 13-17, 2025
• First presentation: May 13, 2025 (6:00-7:30 PM CDT)
• Second presentation: May 17, 2025 (11:15-11:30 AM CDT)

Presentation materials will be available in the Science section of Century's website after the event.

Positive

• Advancing iPSC-derived cell therapy pipeline with two key presentations at ASGCT
• Development of enhanced TGF-b neutralizing technology for better solid tumor elimination
• Progress in CD19 CAR T-cell therapy showing comparable performance to healthy donor T cells

Negative

• None.

PHILADELPHIA, April 28, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today announced two presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting, which is being held from May 13-17, 2025, at the New Orleans Ernest N. Morial Convention Center in New Orleans, LA. The presentations will highlight data supporting the company’s emerging preclinical cell therapy pipeline and investigational programs for autoimmune diseases and cancer.

Details of the presentations are as follows:

Abstract Number: 1826
Poster Number: 740
Title: Armoring iPSC-derived allogeneic therapies with a TGF-b neutralizing synthetic receptor that enhances solid tumor elimination in TME-mimicking conditions in vitro
Session Title: Poster Abstract Session
Session Date/Time: Tuesday, May 13, 2025, 6:00 p.m. – 7:30 p.m. CDT
Presenter: Raisa Uchurova, Ph.D., Principal Scientist at Century Therapeutics

Abstract Number: 1857
Title: Generation of iPSC-derived CD4+ and CD8+ CD19 CAR ab T cells with in vivo tumor control and cell expansion comparable to healthy donor T cells
Session Title: Oral Abstract Session
Session Date/Time: Saturday, May 17, 2025, 11:15 a.m. – 11:30 a.m. CDT
Presenter: Dar Heinze, M.D., Associate Director at Century Therapeutics

Additional information, including the accepted abstracts, can be accessed on the ASGCT 28th Annual Meeting website. Presentation materials will be made available in the Science section under Scientific Resources of the company’s website following the event.

About Century Therapeutics
Century Therapeutics (NASDAQ: IPSC) is a clinical-stage biotechnology company leveraging its expertise in cellular reprogramming, genetic engineering, and manufacturing to develop cell therapies with the potential to provide meaningful advantages over existing cell therapies. Century’s genetically engineered, iPSC-derived cell therapy pipeline includes programs designed to address autoimmune diseases and cancers. Century believes its commitment to developing off-the-shelf cell therapies will expand patient access and provide an opportunity to advance the course of autoimmune disease and cancer care. For more information on Century Therapeutics, please visit www.centurytx.com and connect with us on LinkedIn.

Forward-Looking Statements
This press release and statements made in connection therewith contain forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding our clinical development plans and timelines are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this press release are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control, including, among others: our ability to successfully advance our current and future product candidates through development activities, preclinical studies, and clinical trials; our dependence on the success of our lead product candidate, CNTY-101; our ability to progress CNTY-101 through clinical development; our ability to meet development milestones on anticipated timelines; uncertainties inherent in the results of preliminary data, pre-clinical studies and earlier-stage clinical trials, which may not be predictive of final results or the results of later-stage clinical trials; our ability to obtain FDA clearance of our future IND submissions and commence and complete clinical trials on expected timelines, or at all; our reliance on the maintenance of certain key collaborative relationships for the manufacturing and development of our product candidates; the timing, scope and likelihood of regulatory filings and approvals, including final regulatory approval of our product candidates; the impact of geopolitical issues, banking instability and inflation on our business and operations, supply chain and labor force; the performance of third parties in connection with the development of our product candidates, including third parties conducting our clinical trials as well as third-party suppliers and manufacturers; our ability to successfully commercialize our product candidates and develop sales and marketing capabilities, if our product candidates are approved; our ability to recruit and maintain key members of management and our ability to maintain and successfully enforce adequate intellectual property protection. These and other risks and uncertainties are described more fully in the “Risk Factors” section of our most recent filings with the Securities and Exchange Commission and available at www.sec.gov. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

For More Information:

Century Therapeutics
Morgan Conn, PhD
Chief Financial Officer
investor.relations@centurytx.com

JPA Health
Sarah McCabe
smccabe@jpa.com

FAQ

What will Century Therapeutics (IPSC) present at ASGCT 2025 Annual Meeting?

Century Therapeutics will present two studies at ASGCT 2025: one on TGF-b neutralizing receptors for solid tumors (Poster #740) and another on iPSC-derived CAR T cells for tumor control, scheduled for May 13 and May 17, 2025, in New Orleans.

How is Century Therapeutics (IPSC) developing cancer treatment using iPSC technology?

Century Therapeutics is developing iPSC-derived cell therapies that include CD4+ and CD8+ CD19 CAR T cells for tumor control, and enhanced solid tumor treatments using TGF-b neutralizing synthetic receptors.

When are Century Therapeutics (IPSC) ASGCT 2025 presentation dates?

Century Therapeutics will present on Tuesday, May 13, 2025 (6:00-7:30 p.m. CDT) and Saturday, May 17, 2025 (11:15-11:30 a.m. CDT) at the New Orleans Ernest N. Morial Convention Center.

What are the key findings of Century Therapeutics (IPSC) tumor control study?

The study shows that Century's iPSC-derived CD4+ and CD8+ CD19 CAR T cells demonstrated in vivo tumor control and cell expansion comparable to healthy donor T cells.

Where can investors find Century Therapeutics (IPSC) ASGCT 2025 presentation materials?

Investors can access Century Therapeutics' ASGCT presentation materials in the Science section under Scientific Resources on the company's website after the event.